Purinergic approach to effective glioma treatment with temozolomide reveals enhanced anti-cancer effects mediated by P2X7 receptor

Kim, 2021, Genetic architectures and cell-of-origin in glioblastoma, Front. Oncol., 10, 10.3389/fonc.2020.615400

Vollmann-Zwerenz, 2020, Tumor cell invasion in glioblastoma, Int. J. Mol. Sci., 21, 1, 10.3390/ijms21061932

Seker-Polat, 2022, Tumor cell infiltration into the brain in glioblastoma: from mechanisms to clinical perspectives, Cancers (Basel), 14, 443, 10.3390/cancers14020443

Taal, 2015, CNS oncology chemotherapy in glioma, CNS Oncol., 4, 179, 10.2217/cns.15.2

Brada, 2010, Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade glioma, J. Clin. Oncol., 28, 4601, 10.1200/JCO.2009.27.1932

Ramalho, 2019, Biophysical interaction of temozolomide and its active metabolite with biomembrane models: the relevance of drug-membrane interaction for glioblastoma Multiforme therapy, Eur. J. Pharm. Biopharm., 136, 156, 10.1016/j.ejpb.2019.01.015

Bae, 2014, Toxicity profile of temozolomide in the treatment of 300 malignant glioma patients in Korea, J. Korean Med. Sci., 29, 980, 10.3346/jkms.2014.29.7.980

Lee, 2016, Temozolomide resistance in glioblastoma multiforme, Genes Dis., 3, 198, 10.1016/j.gendis.2016.04.007

Cuevas, 2004, Differentiation-inducing activity of neomycin in cultured rat glioma cells, Neurol. Res., 26, 401, 10.1179/016164104225016317

Dreyfus, 2018, Reprogramming glioma cell cultures with retinoic acid: additional arguments for reappraising the potential of retinoic acid in the context of personalized glioma therapy, Glioma, 1, 66, 10.4103/glioma.glioma_3_18

Burnstock, 2006, Pathophysiology and therapeutic potential of purinergic signaling, Pharmacol. Rev., 58, 10.1124/pr.58.1.5

Lara, 2020, P2X7 in Cancer: from molecular mechanisms to therapeutics, Front. Pharmacol., 11, 10.3389/fphar.2020.00793

Sarti, 2021, P2X7: a receptor with a split personality that raises new hopes for anti-cancer therapy, Purinergic Signal, 17, 175, 10.1007/s11302-021-09783-w

Gelin, 2020

Shabbir, 2008, Effect of extracellular ATP on the growth of hormone-refractory prostate cancer in vivo, BJU Int., 102, 108, 10.1111/j.1464-410X.2008.07578.x

Ceruti, 2013, Adenosine signaling in glioma cells, 13

Spychala, 2000, Tumor-promoting functions of adenosine, Pharmacol. Ther., 87, 161, 10.1016/S0163-7258(00)00053-X

Ji, 2018, Involvement of P2X7 receptor in proliferation and migration of human glioma cells, Biomed. Res. Int., 2018, 10.1155/2018/8591397

Bergamin, 2019

Gehring, 2012, P2X7 receptor activation leads to increased cell death in a radiosensitive human glioma cell line, Purinergic Signal, 8, 729, 10.1007/s11302-012-9319-2

Yan, 2019, CD73 promotes glioblastoma pathogenesis and enhances its chemoresistance via A2B adenosine receptor signaling, J. Neurosci., 39, 4387, 10.1523/JNEUROSCI.1118-18.2019

Torres, 2019, Extracellular adenosine promotes cell migration/invasion of glioblastoma stem-like cells through A3 adenosine receptor activation under hypoxia, Cancer Lett., 446, 112, 10.1016/j.canlet.2019.01.004

Liang, 2007, In vitro scratch assay: a convenient and inexpensive method for analysis of cell migration in vitro, Nat. Protoc., 2, 329, 10.1038/nprot.2007.30

McCarthy, 2019, Full-length P2X7 structures reveal how Palmitoylation Prevents Channel desensitization, Cell, 179, 10.1016/j.cell.2019.09.017

Koes, 2013, Lessons learned in empirical scoring with smina from the CSAR 2011 benchmarking exercise, J. Chem. Inf. Model., 53, 1893, 10.1021/ci300604z

Pegoraro, 2021, P2X7 variants in oncogenesis, Cells, 10, 189, 10.3390/cells10010189

Jacques, 2017, Nucleotide P2Y13-stimulated phosphorylation of CREB is required for ADP-induced proliferation of late developing retinal glial progenitors in culture, Cell. Signal., 35, 95, 10.1016/j.cellsig.2017.03.019

Dsouza, 2021, Characterization of potency of the P2Y13 receptor agonists: a Meta-analysis, Int. J. Mol. Sci. Artic., 10.3390/ijms22073468

Cavaliere, 2015, Purinergic signaling: a common pathway for neural and mesenchymal stem cell maintenance and differentiation, Front. Cell. Neurosci., 9, 1, 10.3389/fncel.2015.00211

Di Virgilio, 2018, Extracellular ATP and P2 purinergic signalling in the tumour microenvironment, Nat. Rev. Cancer, 18, 601, 10.1038/s41568-018-0037-0

Ziberi, 2020, Transition markers and P2X7 receptors is associated to increased invasiveness caused by P2X7 receptor, Cells, 9, 85, 10.3390/cells9010085

Sluyter, 2017, The P2X7 receptor, Adv. Exp. Med. Biol., 1051, 17, 10.1007/5584_2017_59

Douguet, 2021, A small-molecule P2RX7 activator promotes anti-tumor immune responses and sensitizes lung tumor to immunotherapy, Nat. Commun., 12, 1, 10.1038/s41467-021-20912-2

Martinez, 2019, P2X7 receptor in cardiovascular disease: the heart side, Clin. Exp. Pharmacol. Physiol., 46, 513, 10.1111/1440-1681.13079

Solini, 2019, Role of the P2X7 receptor in the pathogenesis of type 2 diabetes and its microvascular complications, Curr. Opin. Pharmacol., 47, 75, 10.1016/j.coph.2019.02.009

Burnstock, 2004, Cellular distribution and functions of P2 receptor subtypes in different systems, Int. Rev. Cytol., 240, 31, 10.1016/S0074-7696(04)40002-3

Barden, 2014, Non-functional P2X7: a novel and ubiquitous target in human Cancer, J. Clin. Cell Immunol., 05, 10.4172/2155-9899.1000237

Moreau, 2020, Orthosteric muscarinic receptor activation by the insect repellent IR3535 opens new prospects in insecticide-based vector control, Sci. Rep., 10, 1, 10.1038/s41598-020-63957-x

Lambrecht, 2000, Agonists and antagonists acting at P2X receptors: selectivity profiles and functional implications, Naunyn Schmiedeberg’s Arch. Pharmacol., 362, 340, 10.1007/s002100000312

Donnelly-Roberts, 2009, Mammalian P2X7 receptor pharmacology: comparison of recombinant mouse, rat and human P2X7 receptors, Br. J. Pharmacol., 157, 1203, 10.1111/j.1476-5381.2009.00233.x